New oral anticoagulants for atrial fibrillation: are they worth the risk?

Target-specific oral anticoagulants: should we switch from warfarin? Tex Heart Inst J (2015) 0.81

Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users. Adv Ther (2015) 0.76

Findings of transoesophageal echocardiogram in appropriately anticoagulated patients with persistent atrial fibrillation prior to planned cardioversion. BMC Cardiovasc Disord (2017) 0.75

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98

Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation (2006) 11.78

Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2010) 9.18

Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace (2012) 7.33

Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 6.47

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet (2010) 6.31

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med (2013) 5.19

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.82

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med (2010) 4.16

Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35

Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost (2010) 3.03

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost (2011) 2.87

Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest (2006) 2.79

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ (2011) 2.65

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost (2012) 2.61

Removal of dabigatran by hemodialysis. Am J Kidney Dis (2012) 2.52

Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost (2010) 2.47

Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost (2011) 2.22

Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol (2012) 1.79

Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke (2010) 1.79

2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2011) 1.73

Anticoagulants in heart disease: current status and perspectives. Eur Heart J (2007) 1.73

Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2012) 1.62

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost (2011) 1.59

Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost (2009) 1.58

Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet (2001) 1.49

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke (2013) 1.37

Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit (2010) 1.36

Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation (2013) 1.31

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (2012) 1.26

Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol (2012) 1.23

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke (2012) 1.15

Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol (2013) 1.06

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart (2012) 1.05

Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology (2012) 1.05

Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes (2013) 1.00

Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One (2012) 0.99

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thromb Haemost (2012) 0.90

Pharmacologic interventions for reversing the effects of oral anticoagulants. Am J Health Syst Pharm (2013) 0.89

Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark. J Med Econ (2012) 0.88

Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison. Thromb Haemost (2012) 0.83

The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study. Can J Cardiol (2007) 0.80

Novel anticoagulants in atrial fibrillation stroke prevention. Ther Adv Chronic Dis (2012) 0.79

Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Drugs (2013) 0.77

Role of interleukin-1 inhibitors in the management of gout. Pharmacotherapy (2013) 0.88

Olmesartan and drug-induced enteropathy. P T (2014) 0.75

786: PRESCRIBING PATTERNS FOR PROPHYLACTIC ANTIEPILEPTIC DRUGS IN THE NEUROSURGICAL INTENSIVE CARE UNIT. Crit Care Med (2016) 0.75